Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Yoshiko Umeyama"'
Autor:
Emi Noguchi, Takashi Yamanaka, Hirofumi Mukai, Naohito Yamamoto, Chi-Feng Chung, Yen-Shen Lu, Dwan-Ying Chang, Joohyuk Sohn, Gun Min Kim, Kyung-Hun Lee, Soo-Chin Lee, Tsutomu Iwasa, Hiroji Iwata, Kenichi Watanabe, Kyung Hae Jung, Yuko Tanabe, Seok Yun Kang, Hiroyuki Yasojima, Kenjiro Aogi, Eriko Tokunaga, Sung Hoon Sim, Yoon Sim Yap, Koji Matsumoto, Ling-Ming Tseng, Yoshiko Umeyama, Kazuki Sudo, Yuki Kojima, Tomomi Hata, Aya Kuchiba, Taro Shibata, Kenichi Nakamura, Yasuhiro Fujiwara, Kenji Tamura, Kan Yonemori
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-10 (2024)
Abstract Palbociclib combined with endocrine therapy is approved for treating patients with hormone-receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer; however, data on palbociclib combined with t
Externí odkaz:
https://doaj.org/article/3cba658e7441401e9b9e50ad16a29171
Autor:
Masatoshi Kudo, Kenta Motomura, Yoshiyuki Wada, Yoshitaka Inaba, Yasunari Sakamoto, Masayuki Kurosaki, Yoshiko Umeyama, Yoichi Kamei, Junichiro Yoshimitsu, Yosuke Fujii, Mana Aizawa, Paul B. Robbins, Junji Furuse
Publikováno v:
Liver Cancer, Pp 1-11 (2021)
Introduction: Combining an immune checkpoint inhibitor with a targeted antiangiogenic agent may leverage complementary mechanisms of action for the treatment of advanced/metastatic hepatocellular carcinoma (aHCC). Avelumab is a human anti-PD-L1 IgG1
Externí odkaz:
https://doaj.org/article/b8be2ef681554e6887c3892833ec2d08
Autor:
Masato Takahashi, Norikazu Masuda, Reiki Nishimura, Kenichi Inoue, Shinji Ohno, Hiroji Iwata, Satoshi Hashigaki, Yasuaki Muramatsu, Yoshiko Umeyama, Masakazu Toi
Publikováno v:
Cancer Medicine, Vol 9, Iss 14, Pp 4929-4940 (2020)
Abstract Palbociclib is a highly selective, reversible, oral inhibitor of cyclin‐dependent kinases 4 and 6 that is approved to treat hormone receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer. An open‐l
Externí odkaz:
https://doaj.org/article/3f132e5f207c43dc8551b28f7407faeb
Autor:
Yoshihiko Tomita, Hirotsugu Uemura, Mototsugu Oya, Nobuo Shinohara, Tomonori Habuchi, Yosuke Fujii, Yoichi Kamei, Yoshiko Umeyama, Angel H. Bair, Brian I. Rini
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-11 (2019)
Abstract Background A prospective, randomised phase II study demonstrated clinical benefit of axitinib dose titration in a subset of treatment-naïve patients treated with axitinib for metastatic renal cell carcinoma. This analysis evaluated patient
Externí odkaz:
https://doaj.org/article/e3c513bc63be438997c0bbcecb38ef8c
Autor:
Takayuki Ueno, Louis W.C. Chow, Wonshik Han, Chiun Sheng Huang, G Bruce Mann, Satoshi Morita, Hironori Haga, Elham Fakhrejahani, Takayuki Kobayashi, Kenichi Inoue, Mariko Tokiwa, Hirofumi Suwa, Tomoyuki Aruga, Sachiko Minamiguchi, Yosuke Yamada, Yuko Tanabe, Masahiro Takada, Toshinari Yamashita, Hiroji Iwata, Chi-Feng Chung, Sachiko Takahara, Eriko Tokunaga, Shigeru Imoto, Eun Sook Lee, Yasuaki Sagara, Jee Hyun Kim, Richard H DeBoer, Hyun-Ah Kim, Hung Wen Lai, Ming-Feng Hou, Michelle White, Yoshiko Umeyama
Publikováno v:
Cancer Research. 83:P5-09
Background: Early biologic response to endocrine therapy, such as changes in Ki67 labeling index (LI), has been suggested to predict long-term outcomes in hormone sensitive breast cancer. The addition of a CDK4/6 inhibitor to endocrine therapy has be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bb53d5840e126a022215ca6a15039878
https://doi.org/10.1158/1538-7445.sabcs22-p5-09-01
https://doi.org/10.1158/1538-7445.sabcs22-p5-09-01
Autor:
Cynthia Huang Bartlett, Linda S. Wood, Yuan Liu, Zhe Zhang, Jean-Claude Marshall, Olivia Fletcher, Hiroji Iwata, Masakazu Toi, Patrick Schnell, Yuko Mori, Massimo Cristofanilli, Richard S. Finn, Nicholas C. Turner, Yoshiko Umeyama, Jillian G. Johnson
Publikováno v:
The Oncologist
Background The most frequently reported treatment‐related adverse event in clinical trials with the cyclin‐dependent kinase 4/6 (CDK4/6) inhibitor palbociclib is neutropenia. Allelic variants in ABCB1 and ERCC1 might be associated with early occu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::421549dbe69cf598b3a5b274298dd590
http://europepmc.org/articles/PMC8265363
http://europepmc.org/articles/PMC8265363
Autor:
Satoshi Hashigaki, Masakazu Toi, Yoshiaki Rai, Kenichi Inoue, Hiroji Iwata, Yasuaki Muramatsu, Chikako Shimizu, Shinji Ohno, Shoichiro Ohtani, Norikazu Masuda, Hirofumi Mukai, Yoshiko Umeyama
Publikováno v:
Breast Cancer (Tokyo, Japan)
BackgroundIn the double-blind, phase 3 PALOMA-2 and PALOMA-3 studies, palbociclib plus endocrine therapy (ET) demonstrated significant improvement in progression-free survival versus placebo plus ET in patients with hormone receptor‒positive/human
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f73aa4f24981f4e43eb096ac6b89b203
https://doi.org/10.1007/s12282-020-01162-4
https://doi.org/10.1007/s12282-020-01162-4
Autor:
Kenichi Inoue, Norikazu Masuda, Shinji Ohno, Reiki Nishimura, Masakazu Toi, Satoshi Hashigaki, Hiroji Iwata, Masato Takahashi, Yasuaki Muramatsu, Yoshiko Umeyama
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 9, Iss 14, Pp 4929-4940 (2020)
Cancer Medicine, Vol 9, Iss 14, Pp 4929-4940 (2020)
Palbociclib is a highly selective, reversible, oral inhibitor of cyclin‐dependent kinases 4 and 6 that is approved to treat hormone receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer. An open‐label, sin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bad5edda8ca51ac1f1f27f7ce9a62c67
http://europepmc.org/articles/PMC7367628
http://europepmc.org/articles/PMC7367628
Autor:
Tomoyuki Kato, Toshio Takagi, Robert J. Motzer, Yoichi Kamei, Toni K. Choueiri, Shingo Hatakeyama, Wataru Obara, Hideaki Miyake, Kazuyuki Numakura, Yosuke Fujii, Hiro-omi Kanayama, Motohide Uemura, Masatoshi Eto, Yoshiko Umeyama, Alessandra di Pietro, Hirotsugu Uemura, Yoshihiko Tomita, Mototsugu Oya
Publikováno v:
Cancer Science
The phase 3 JAVELIN Renal 101 trial of avelumab + axitinib vs sunitinib in patients with treatment‐naive advanced renal cell carcinoma (RCC) demonstrated significantly improved progression‐free survival (PFS) and higher objective response rate (O
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a76222f74dcfc9408334e05144a413d
https://doi.org/10.1111/cas.14294
https://doi.org/10.1111/cas.14294
Autor:
Yoshihiko Tomita, Robert J. Motzer, Toni K. Choueiri, Brian I. Rini, Hirotsugu Uemura, Mototsugu Oya, Laurence Albiges, Yosuke Fujii, Yoshiko Umeyama, Bo Huang, Alessandra Di Pietro, Manuela Schmidinger
Publikováno v:
Journal of Clinical Oncology. 41:670-670
670 Background: Analyses from the phase 3 JAVELIN Renal 101 trial (NCT02684006) suggested that CRP levels at baseline (BL) and early after treatment may predict outcomes with A + Ax in patients with aRCC. In addition, many patients with International
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e19c4d3600e13d63a8a2e3264dd5e811
https://doi.org/10.1200/jco.2023.41.6_suppl.670
https://doi.org/10.1200/jco.2023.41.6_suppl.670